Base excision repair capacity as a determinant of prognosis and therapy response in colon cancer patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10383611" target="_blank" >RIV/00216208:11110/18:10383611 - isvavai.cz</a>

Alternative codes found

RIV/68378041:_____/18:00495532 RIV/00216208:11120/18:43917161 RIV/00216208:11140/18:10383611 RIV/00669806:_____/18:10383611 and 2 more

Result on the web

<a href="https://doi.org/10.1016/j.dnarep.2018.09.006" target="_blank" >https://doi.org/10.1016/j.dnarep.2018.09.006</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.dnarep.2018.09.006" target="_blank" >10.1016/j.dnarep.2018.09.006</a>

Result language

angličtina

Original language name

Base excision repair capacity as a determinant of prognosis and therapy response in colon cancer patients

Original language description

The DNA-damaging agent 5-fluorouracil represents the most commonly used chemotherapeutic drug for colorectal cancer patients. DNA lesions associated with 5-fluorouracil therapy are primarily repaired by base excision repair (BER) and mismatch repair (MMR) pathways. Published evidence suggests that the individual DNA repair capacity (DRC) may affect a patient&apos;s prognosis and response to chemotherapy. With this in mind, we designed a prospective study of which the main aim was to investigate BER-DRC in relation to 5-fluorouracil response as potential predictive and/or prognostic biomarker. BER-DRC was supplemented by a microsatellite instability (MSI) analysis which represents an indirect marker of MMR activity in the tumor. All parameters were measured in paired samples of tumor tissue and non-malignant adjacent mucosa of 123 incident colon cancer patients. Our results indicate that BER-DRC in non-malignant adjacent mucosa was positively associated with overall survival (P = 0.007) and relapse-free survival (P = 0.04). Additionally, in multivariate analysis, good therapy responders in TNM stage II and III with an elevated BER-DRC in mucosa exhibited better overall survival. Moreover, the overall survival of these patients was even better in the presence of a decreased BER-DRC in tumor tissue. The ratio of BER-DRC in tumor tissue over BER-DRC in mucosa positively correlated with advanced tumor stage (P = 0.003). With respect to MSI, we observed that MSI-high tumors were mostly localized in proximal colon; however, in our cohort, the MSI status affected neither patients&apos; prognosis nor survival. In summary, the results of the present study suggest that the level of BER-DRC is associated with patients&apos; survival. BER-DRC represents a potential prognostic biomarker, applicable for prediction of therapy response and useful for individual approach to patients. Copyright (C) 2018. Published by Elsevier B.V.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

10600 - Biological sciences

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

DNA Repair

ISSN

1568-7864

e-ISSN

—

Volume of the periodical

72

Issue of the periodical within the volume

December

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

9

Pages from-to

77-85

UT code for WoS article

000452931200008

EID of the result in the Scopus database

2-s2.0-85054467789